Related references
Note: Only part of the references are listed.Cytotoxic Chemotherapy and CD4+Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Zhi-Chun Ding et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Sophie Viaud et al.
CANCER RESEARCH (2011)
Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide
Federica Moschella et al.
CANCER RESEARCH (2011)
Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature
Pawel Muranski et al.
IMMUNITY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Human TH17 Cells Are Long-Lived Effector Memory Cells
Ilona Kryczek et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Ole Audun Werner Haabeth et al.
NATURE COMMUNICATIONS (2011)
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype
Zhi-Chun Ding et al.
BLOOD (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Kavya Rakhra et al.
CANCER CELL (2010)
CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
Rinke Bos et al.
CANCER RESEARCH (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase
Andrea Schietinger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
CD4+ T Cells Elicit Host Immune Responses to MHC Class II- Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells
Yolanda C. Nesbeth et al.
JOURNAL OF IMMUNOLOGY (2010)
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers
Maha Ayyoub et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
Ilona Kryczek et al.
BLOOD (2009)
被撤回的出版物: Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells (Retracted article. See vol. 76, pg. 2490, 2016)
Kimberly A. Shafer-Weaver et al.
CANCER RESEARCH (2009)
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Natalia Martin-Orozco et al.
IMMUNITY (2009)
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Naomi N. Hunder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immune-potentiating effects chemotherapeutic drug of the cyclophosphamide
Sven Brode et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen-specific manner
Yoshinobu Koguchi et al.
BLOOD (2007)
Rapid default transition of CD4 T cell effectors to functional memory cells
K. Kai McKinstry et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
Patricia A. Darrah et al.
NATURE MEDICINE (2007)
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration
Laura Bracci et al.
CLINICAL CANCER RESEARCH (2007)
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity
P Horna et al.
BLOOD (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
AP Rapoport et al.
NATURE MEDICINE (2005)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff et al.
TRENDS IN IMMUNOLOGY (2005)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Tumor-specific CD4+ T cells have a major post-licensing role in CTL mediated anti-tumor immunity
AL Marzo et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
